基于医院采购数据对美国电生理消融市场的追踪显示，脉冲电场消融（PFA）在2026年三季度已占美国消融导管销量的59%，高于二季度的58%和上年同期的49%，但渗透提速放缓，2026年以来每季度仅提升约2个百分点，而2025年均为5个百分点，模型预计2029年底渗透率达75%-80%。射频（RF）占比降至40%，冷冻消融仅剩1%；三季度冷冻销量同比下降33%、RF下降11%、PFA增长30%，带动样本整体消融导管销量同比增长9%，较此前四个季度17%的均值明显减速。竞争格局趋于拥挤，美敦力、强生持续侵蚀波士顿科学的先发份额，雅培亦在开辟细分市场。价格方面，PFA导管三季度均价为8400美元，略低于2026年一季度8600美元的峰值，双能量新产品上市价仅4600美元；
Hospital purchasing data show pulsed field ablation (PFA) accounted for 59% of U.S. ablation catheter volume in 3Q, up from 58% in 2Q and 49% a year ago, though the incremental gains are narrowing: PFA penetration has risen only about 2pts per quarter in 2026 versus an average of 5pts per quarter in 2025, and Barclays still models 75-80% penetration by YE29. Radiofrequency devices fell to 40% share and cryo to just 1%; cryo unit volume declined 33% YOY, RF fell 11% and PFA rose 30%, driving overall sample ablation catheter volume up 9% YOY, a deceleration from 17% average growth over the prior four quarters. The competitive landscape is crowding, with Medtronic and JNJ eroding Boston Scientific's early lead and Abbott carving out a niche. Blended PFA pricing was $8,400 in 3Q, slightly below the 1Q26 peak of $8,600, while recently approved dual-energy products launched at ASPs of just $4,600. Price/mix contributed 16-18pts of growth in 2024-25 but is on track to fall to about 6pts in 20